Evidence map›Paper›PMID 38276006›Full record

ArticlePharmaceuticals (Basel, Switzerland)2024

Combination Treatment with Liposomal Doxorubicin and Inductive Moderate Hyperthermia for Sarcoma Saos-2 Cells.

Valerii E Orel, Anatoliy G Diedkov, Vasyl V Ostafiichuk, Oleksandra O Lykhova, Denys L Kolesnyk, Valerii B Orel, Olga Yo Dasyukevich, Oleksandr Yu Rykhalskyi, Serhii A Diedkov, Anna B Prosvietova

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Valerii E OrelNational Cancer Institute, 33/43 Zdanovska Str., 03022 Kyiv, Ukraine.ORCID 0000-0002-6319-4215
Anatoliy G DiedkovNational Cancer Institute, 33/43 Zdanovska Str., 03022 Kyiv, Ukraine.
Vasyl V OstafiichukNational Cancer Institute, 33/43 Zdanovska Str., 03022 Kyiv, Ukraine.
Oleksandra O LykhovaR.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, 45 Vasylkivska Str., 03022 Kyiv, Ukraine.
Denys L KolesnykR.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, 45 Vasylkivska Str., 03022 Kyiv, Ukraine.
Valerii B OrelNational Cancer Institute, 33/43 Zdanovska Str., 03022 Kyiv, Ukraine.ORCID 0000-0003-3653-0823
Olga Yo DasyukevichNational Cancer Institute, 33/43 Zdanovska Str., 03022 Kyiv, Ukraine.
Oleksandr Yu RykhalskyiNational Cancer Institute, 33/43 Zdanovska Str., 03022 Kyiv, Ukraine.
Serhii A DiedkovNational Cancer Institute, 33/43 Zdanovska Str., 03022 Kyiv, Ukraine.ORCID 0000-0003-1432-2097
Anna B ProsvietovaNational Technical University of Ukraine "Igor Sikorsky Kyiv Polytechnic Institute", 16/2 Yangel Str., 03056 Kyiv, Ukraine.
National Cancer Institute · UANational Technical University of Ukraine “Igor Sikorsky Kyiv Polytechnic Institute” · UAR.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology · UA

Funding

Ministry of Health of Ukraine, To develop a method of antitumor therapy of primary malignant bone tumors based on magne-tochemical technology using nanocomplexes ВН.14.01.07.204-23
6 · The paper itself

Abstract

Despite efforts in osteosarcoma (OS) research, the role of inductive moderate hyperthermia (IMH) in delivering and enhancing the antitumor effect of liposomal doxorubicin formulations (LDOX) remains unresolved. This study investigated the effect of a combination treatment with LDOX and IMH on Saos-2 human OS cells. We compared cell viability using a trypan blue assay, apoptosis and reactive oxygen species (ROS) measured by flow cytometry and pro-apoptotic Bax protein expression examined by immunocytochemistry in response to IMH (42 MHz frequency, 15 W power for 30 min), LDOX (0.4 μg/mL), and LDOX plus IMH. The lower IC

Indexed as

antitumor effectBax proteincombination treatmentearly apoptosisinductive moderate hyperthermialiposomal doxorubicinosteosarcomareactive oxygen speciesSaos-2 cellstumor cell heterogeneity

Identifiers

PMID38276006
PMCPMC10819935
OpenAlexW4391027134

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.